Cleveland BioLabs, Inc. (
Cleveland BioLabs Director of Business Development, Alan Wolfman PhD., will give a presentation discussing Protectan CBLB502 as both a protectant and treatment for acute radiation syndrome (ARS) stemming from radiation exposure. The presentation will focus on the most recent research progress demonstrating CBLB502's effectiveness in treating both hematopoietic and gastrointestinal syndromes. The presentation will also highlight developmental aspects of Protectan CBLB502 indicating that it can be rapidly produced and stockpiled as the most versatile compound addressing ARS.
Earlier this year, Cleveland BioLabs submitted Protectan CBLB502 to the Department of Defense (DoD) in response to a Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of ARS. The DOD RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter.
Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs, stated, "We look forward to sharing Protectan CBLB502's recent development progress at the BARDA forum. CBLB502's unique abilities to mitigate the damaging effects of radiation on the gastrointestinal system as well as demonstrate significant survival benefits are a breakthrough in this field of study. We believe that CBLB502 presents the best solution for the DoD's requirements and expect the DoD to make its decision on the RFP later this year."
The goal of the BARDA industry Day is to provide an open forum for companies interested in working with the Federal Government to showcase technological advances in medical countermeasures to manmade and naturally occurring threats. Presenters will demonstrate the progress of current activities in advanced research and development of medical countermeasures that will contribute to the success of the HHS Pandemic Influenza Plan, Project BioShield, BARDA, and the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006.
Contact:
The Global Consulting Group
Rachel Levine
T: (646) 284-9439
E: Email Contact